Oppenheimer Asset Management Inc. Takes $77,000 Position in AxoGen, Inc (AXGN)

Share on StockTwits

Oppenheimer Asset Management Inc. purchased a new position in shares of AxoGen, Inc (NASDAQ:AXGN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,762 shares of the medical equipment provider’s stock, valued at approximately $77,000.

Several other hedge funds also recently bought and sold shares of AXGN. Peregrine Capital Management LLC grew its holdings in shares of AxoGen by 35.2% in the 4th quarter. Peregrine Capital Management LLC now owns 434,562 shares of the medical equipment provider’s stock worth $8,878,000 after purchasing an additional 113,063 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of AxoGen by 4.9% in the 3rd quarter. Vanguard Group Inc now owns 1,585,119 shares of the medical equipment provider’s stock worth $58,412,000 after purchasing an additional 74,226 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of AxoGen by 4.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,585,119 shares of the medical equipment provider’s stock worth $58,412,000 after purchasing an additional 74,226 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of AxoGen by 128.8% in the 3rd quarter. Legal & General Group Plc now owns 12,124 shares of the medical equipment provider’s stock worth $447,000 after purchasing an additional 6,824 shares during the last quarter. Finally, Teachers Advisors LLC grew its holdings in shares of AxoGen by 5.2% in the 3rd quarter. Teachers Advisors LLC now owns 66,926 shares of the medical equipment provider’s stock worth $2,466,000 after purchasing an additional 3,315 shares during the last quarter. Institutional investors and hedge funds own 88.42% of the company’s stock.

Several equities research analysts have recently weighed in on the stock. BidaskClub lowered shares of AxoGen from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th. Cantor Fitzgerald lowered their target price on shares of AxoGen from $45.00 to $43.00 and set an “overweight” rating on the stock in a report on Tuesday, October 30th. ValuEngine lowered shares of AxoGen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. Leerink Swann reaffirmed an “outperform” rating and issued a $55.00 target price on shares of AxoGen in a report on Tuesday, October 30th. Finally, BTIG Research assumed coverage on shares of AxoGen in a report on Wednesday, November 14th. They issued a “neutral” rating on the stock. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. AxoGen presently has a consensus rating of “Buy” and a consensus target price of $41.40.

Shares of NASDAQ AXGN opened at $17.67 on Thursday. AxoGen, Inc has a 12-month low of $14.13 and a 12-month high of $56.85.

In related news, General Counsel Gregory Gene Freitag sold 45,000 shares of the company’s stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $33.00, for a total transaction of $1,485,000.00. Following the transaction, the general counsel now owns 95,865 shares in the company, valued at approximately $3,163,545. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 7.86% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This report was first published by Highlight Press and is owned by of Highlight Press. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://highlightpress.com/2019/02/21/oppenheimer-asset-management-inc-takes-77000-position-in-axogen-inc-axgn.html.

AxoGen Company Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Read More: Preferred Stock

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc (NASDAQ:AXGN).

Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply